Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Randomized, Double-Blinded Evaluation of Oral Everolimus (RAD001) Plus Bevacizumab vs. Oral Placebo Plus Bevacizumab in the Treatment of Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Brief Summary: This randomized phase II trial studies how well bevacizumab with or without everolimus works in treating patients with recurrent or persistent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab and everolimus may also stop the growth of tumor cells by blocking blood flow to the tumor. It is not yet known whether bevacizumab is more effective when given together with or without everolimus in treating ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: olaparib, Drug: paclitaxel, Drug: Drug: carboplatin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: paclitaxel, Drug: carboplatin | Intervention Type: DRUG; Name: olaparib; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Drug: carboplatin; Assigned to Arm(s): 1
B: Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): N/A
C: Arm Label: Bevacizumab combined with Fluzoparib; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: chemotherapy | Arm Label: Bevacizumab combined with chemotherapy; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: chemotherapy | Arm Label: Fluzoparib; Type: EXPERIMENTAL; Interventions: Drug: Fluzoparib | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Bevacizumab combined with Fluzoparib, Bevacizumab combined with chemotherapy | Intervention Type: DRUG; Name: chemotherapy; Assigned to Arm(s): Bevacizumab combined with Fluzoparib, Bevacizumab combined with chemotherapy | Intervention Type: DRUG; Name: Fluzoparib; Assigned to Arm(s): Fluzoparib
D: Arm Label: Arm I (bevacizumab and everolimus); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Drug: Everolimus, Other: Laboratory Biomarker Analysis | Arm Label: Arm II (bevacizumab and placebo); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Other: Laboratory Biomarker Analysis, Other: Placebo | Intervention Type: BIOLOGICAL; Name: Bevacizumab; Assigned to Arm(s): Arm I (bevacizumab and everolimus), Arm II (bevacizumab and placebo) | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Arm I (bevacizumab and everolimus) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (bevacizumab and everolimus), Arm II (bevacizumab and placebo) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Arm II (bevacizumab and placebo)

Answer: D